Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Aim: We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were ad...
Saved in:
Main Authors: | Amrita Krishnan (Author), Ajay K Nooka (Author), Ajai Chari (Author), Alfred L Garfall (Author), Thomas G Martin (Author), Sandhya Nair (Author), Xiwu Lin (Author), Keqin Qi (Author), Anil Londhe (Author), Lixia Pei (Author), Eric Ammann (Author), Rachel Kobos (Author), Jennifer Smit (Author), Trilok Parekh (Author), Alexander Marshall (Author), Mary Slavcev (Author), Saad Z Usmani (Author) |
---|---|
Format: | Book |
Published: |
Becaris Publishing Limited,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Teclistamab: Mechanism of action, clinical, and translational science
by: Yue Guo, et al.
Published: (2024) -
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab
by: Marie‐Emilie Willemin, et al.
Published: (2024) -
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020) -
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
by: José-Ángel Her, et al.
Published: (2022) -
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020)